345 Treatment with amlitelimab—a novel non-depleting, non-cytotoxic anti-OX40Ligand monoclonal antibody—reduces IL-22 serum levels in a phase 2a randomized, placebo-controlled trial in patients with moderate-to-severe atopic dermatitis

医学 湿疹面积及严重程度指数 安慰剂 斯科拉德 临床终点 内科学 随机对照试验 特应性皮炎 胃肠病学 免疫学 疾病 病理 皮肤科生活质量指数 替代医学
作者
Stephan Weidinger,Michael J. Cork,Adam Reich,Thomas Bieber,Sally Gilbert,Nuala Brennan,Rosamund Wilson,Davide Lucchesi,Natalie Rynkiewicz,Marisa Stebegg,Ben Porter‐Brown
出处
期刊:British Journal of Dermatology [Oxford University Press]
卷期号:188 (Supplement_2) 被引量:8
标识
DOI:10.1093/bjd/ljac140.039
摘要

Abstract OX40Ligand (OX40L) upregulation on antigen-presenting cells (APCs) following antigen presentation contributes to the survival and functional activation of T helper (Th) 2 and Th1/17/22 cells, which are central to the inflammation and pathological outcomes in atopic dermatitis (AD). In a Phase 2a trial (NCT03754309), amlitelimab, a fully human, non-depleting, non-cytotoxic anti-OX40L monoclonal antibody, was effective in treating patients with moderate-to-severe AD. To assess the effects of amlitelimab on interleukin (IL)-22, an important Th22-associated disease mediator of AD. 89 patients with moderate-to-severe AD were enrolled in a Phase 2a randomized, double-blind, placebo-controlled, multicentre trial and randomized 1 : 1 : 1 to intravenous amlitelimab low dose (200 mg loading/100 mg maintenance every 4 weeks [Q4W]; n = 29), high dose (500 mg/250 mg Q4W; n = 30) or placebo (Q4W; n = 29) until week 12. The primary efficacy endpoint was the percentage change in Eczema Area and Severity Index (EASI) from baseline to week 16. Other disease severity measurements included SCORing of Atopic Dermatitis (SCORAD) and validated Investigator Global Assessment (vIGA). Serum was collected at baseline, week 4 and week 16, and further collected at week 24 and week 36 in responders, defined as patients who reached vIGA 0/1 at week 16. IL-22 levels were determined by ultrasensitive single-molecule immunoassay (Simoa). Of 88 subjects who received study treatment, 59 were evaluable at week 16. Amlitelimab was well tolerated with an unremarkable safety profile. The mean percentage change in EASI from baseline at week 16 was −80.12% for amlitelimab low dose and −69.97% for amlitelimab high dose vs. −49.37% for placebo (nominal P-values: 0.009 [amlitelimab low dose vs. placebo] and 0.072 [amlitelimab high dose vs. placebo]). Amlitelimab-treated patients who achieved vIGA 0/1 at week 16 had sustained clinical responses up to week 36. No difference in IL-22 serum levels was found between groups at baseline. IL-22 levels correlated with disease severity at baseline, as measured by EASI and SCORAD (r = 0.53, P < 0.0001; and r = 0.36, P = 0.001; respectively). A significant reduction in IL-22 levels was observed at week 16 in amlitelimab-treated patients (low dose P < 0.0001; high dose P = 0.001), but not in the placebo group (P = 0.381). The amlitelimab-induced decrease in IL-22 levels was maintained until week 36 in those defined as vIGA 0/1 responders at week 16. OX40L blockade on APCs represents a promising novel approach in the treatment of AD by effectively targeting underlying T-cell immune dysregulation. Amlitelimab monotherapy not only provided a sustained and clinically meaningful improvement in disease activity compared with placebo in patients with moderate-to-severe AD, but also significantly decreased serum levels of IL-22, a Th22 cell-associated cytokine involved in the underlying immunopathogenesis of AD.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
xiaoting应助kysl采纳,获得10
刚刚
1秒前
李健的小迷弟应助自由井采纳,获得10
2秒前
klb13完成签到,获得积分0
2秒前
yy发布了新的文献求助20
2秒前
CipherSage应助syx采纳,获得10
3秒前
李健的小迷弟应助GALAXY采纳,获得10
3秒前
kaio完成签到,获得积分10
4秒前
4秒前
大鱼完成签到,获得积分20
4秒前
4秒前
xiao完成签到,获得积分10
4秒前
难过的笑天完成签到,获得积分10
4秒前
5秒前
lailai完成签到 ,获得积分10
5秒前
桐桐应助狂野怜蕾采纳,获得10
5秒前
淡定映之完成签到,获得积分20
5秒前
lynn完成签到,获得积分10
5秒前
Joff_W完成签到,获得积分10
5秒前
Jiang完成签到,获得积分10
6秒前
丘比特应助洁净斑马采纳,获得10
6秒前
xt完成签到,获得积分10
6秒前
liusx123完成签到,获得积分20
8秒前
烂漫念柏发布了新的文献求助10
8秒前
爆米花应助Lancent采纳,获得10
9秒前
9秒前
10秒前
鹿鹿鹿鹿发布了新的文献求助10
10秒前
桀桀桀发布了新的文献求助10
10秒前
11秒前
11秒前
ziyue发布了新的文献求助10
12秒前
乐乐应助yy采纳,获得10
12秒前
12秒前
12秒前
12秒前
Lik完成签到,获得积分10
13秒前
13秒前
napnap完成签到 ,获得积分10
13秒前
lalala发布了新的文献求助10
13秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 360
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3970843
求助须知:如何正确求助?哪些是违规求助? 3515550
关于积分的说明 11178897
捐赠科研通 3250660
什么是DOI,文献DOI怎么找? 1795393
邀请新用户注册赠送积分活动 875828
科研通“疑难数据库(出版商)”最低求助积分说明 805188